Edition:
India

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

14.01USD
1:30am IST
Change (% chg)

$-0.05 (-0.36%)
Prev Close
$14.06
Open
$14.10
Day's High
$14.32
Day's Low
$13.75
Volume
206,214
Avg. Vol
254,584
52-wk High
$43.85
52-wk Low
$11.89

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics Reports Q2 Loss Per Share $1.60
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q2 LOSS PER SHARE $1.60.Q2 EARNINGS PER SHARE ESTIMATE $-1.50 -- REFINITIV IBES DATA.ATARA BIOTHERAPEUTICS EXPECTS NET OFFERING PROCEEDS, EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, TO FUND PLANNED OPERATIONS INTO 2021.  Full Article

Atara Biotherapeutics Announces Pricing Of $150 Mln Public Offering
Friday, 19 Jul 2019 

July 18 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF $150.0 MILLION PUBLIC OFFERING.ATARA BIOTHERAPEUTICS - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 6.9 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $15.28 PER SHARE.  Full Article

Atara Biotherapeutics Announces Proposed Offering Of Common Stock
Friday, 19 Jul 2019 

July 18 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Atara Biotherapeutics Announces Collaborator Presentation Of Positive Phase 1 Clinical Results For Mesothelin-Targeted Car T Immunotherapy
Sunday, 31 Mar 2019 

March 31 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES COLLABORATOR PRESENTATION OF POSITIVE PHASE 1 CLINICAL RESULTS FOR A MESOTHELIN-TARGETED CAR T IMMUNOTHERAPY IN PATIENTS WITH ADVANCED MESOTHELIOMA.ATARA BIOTHERAPEUTICS- MESOTHELIN-TARGETED, AUTOLOGOUS CAR T ADMINISTRATION FOUND GENERALLY WELL-TOLERATED WITH NO CAR T-RELATED TOXICITIES HIGHER THAN GRADE 2.  Full Article

Atara Biotherapeutics Q4 Loss Per Share $1.75
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q4 LOSS PER SHARE $1.75.  Full Article

Atara Biotherapeutics Reports Q2 Loss Per Share Of $1.15
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS.Q2 LOSS PER SHARE $1.15.Q2 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.  Full Article

Atara Biotherapeutics Appoints Utpal Koppikar As Chief Financial Officer
Thursday, 7 Jun 2018 

June 7 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES APPOINTMENT OF UTPAL KOPPIKAR AS CHIEF FINANCIAL OFFICER.ATARA BIOTHERAPEUTICS INC - UTPAL KOPPIKAR HAS JOINED ATARA AS CHIEF FINANCIAL OFFICER, EFFECTIVE IMMEDIATELY.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS.ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019.  Full Article

Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics
Friday, 5 Jan 2018 

Jan 5 (Reuters) - CAMBER CAPITAL MANAGEMENT LLC ::CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING.  Full Article

Atara Biotherapeutics prices public offering of 7 mln shares at $18.25 per share
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $18.25PER SHARE.  Full Article